Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer Business Wire - Fri Apr 17, 7:30AM CDT

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration...

GILD : 137.64 (-0.66%)
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access Business Wire - Tue Apr 14, 11:00AM CDT

– Additional Commitment will Expand Access to Lenacapavir to Reach Another Million People Over the Next 3 Years –

GILD : 137.64 (-0.66%)
MHK
1 Profitable Stock for Long-Term Investors and 2 Facing Challenges StockStory - Mon Apr 13, 11:33PM CDT

1 Profitable Stock for Long-Term Investors and 2 Facing Challenges

MHK : 108.83 (+6.54%)
MRK : 119.07 (+3.13%)
GILD : 137.64 (-0.66%)
GILD
Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks StockStory - Sun Apr 12, 10:35PM CDT

Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks

GILD : 137.64 (-0.66%)
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE Business Wire - Thu Apr 9, 7:30AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD)...

GILD : 137.64 (-0.66%)
TEM : 55.87 (+2.66%)
Gilead to Acquire Tubulis for Up to $5 Billion to Expand Cancer Drug Pipeline Quiver Quantitative, Inc. - Tue Apr 7, 6:40PM CDT

Gilead Sciences ($GILD) said Tuesday it will acquire Germany-based Tubulis GmbH for up to $5 billion, including $3.15 billion upfront and up to $1.85 billion in milestone payments, as the company expands...

GILD : 137.64 (-0.66%)
BMY : 60.17 (+2.05%)
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline Business Wire - Tue Apr 7, 7:30AM CDT

– Acquisition Adds TUB-040, a NaPi2b Targeting ADC for Ovarian Cancer and other Solid Tumors, to Gilead Pipeline – – Industry Leading ADC Platform...

GILD : 137.64 (-0.66%)
Gilead Extends Tender Offer to Acquire Arcellx Business Wire - Wed Apr 1, 3:13PM CDT

Gilead Sciences, Inc. (Nasdaq: GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer remains at a purchase price of (1) $115.00...

GILD : 137.64 (-0.66%)
Gilead Sciences, Inc_ logo and vials -by Melnikov Dmitriy via Shutterstock
Gilead Sciences's Q1 2026 Earnings: What to Expect Barchart - Wed Apr 1, 9:21AM CDT

Gilead Sciences is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth.

XLV : 148.80 (+1.49%)
$SPX : 7,126.06 (+1.20%)
GILD : 137.64 (-0.66%)
Options on cell phone by Trismegist san via Shutterstock
Options Action: Naked Put Trade Ideas for March 31 Barchart - Tue Mar 31, 6:00AM CDT

With market volatility on the rise, put premiums are highly elevated, so it’s a good time to check in on Barchart’s Naked Put Screener.

INTC : 68.50 (unch)
MU : 455.07 (-0.47%)
FCX : 70.21 (+2.83%)
GILD : 137.64 (-0.66%)
DAL : 71.72 (+2.62%)

Barchart Exclusives

Applebee’s and IHOP Owner Dine Brands Looks Ripe For A Buyout Barchart - Sun Apr 19, 2:18PM CDT
Dine Brands has already rallied on activist pressure, but with Applebee’s and IHOP still trading below their strategic value, private equity could be the next catalyst. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.